Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges.
暂无分享,去创建一个
A. Tubaro | E. Cherullo | D. Arcaniolo | C. de Nunzio | Antonio Franco | Francesco Ditonno | Celeste Manfredi | Riccardo Autorino | Eugenio Bologna | L. Licari | M. de Sio | A. Antonelli
[1] G. Andriole,et al. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. , 2023, Prostate cancer and prostatic diseases.
[2] H. Woo,et al. Functional and oncological outcomes after radical prostatectomy in patients with history of surgery for lower urinary tract symptoms related to benign prostatic enlargement: A systematic review with meta-analysis. , 2023, Prostate cancer and prostatic diseases.
[3] M. Cooperberg,et al. Prostate Cancer in Transgender Women in the Veterans Affairs Health System, 2000-2022. , 2023, JAMA.
[4] J. D. de Bono,et al. A Transgender Patient with Prostate Cancer: Lessons Learnt. , 2023, European urology.
[5] M. Emberton,et al. Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients , 2022, Prostate Cancer and Prostatic Diseases.
[6] F. Crocetto,et al. Micro-Ultrasound in the Diagnosis and Staging of Prostate and Bladder Cancer: A Comprehensive Review , 2022, Medicina.
[7] M. Cooperberg,et al. Prostate-Specific Antigen Screening in Transgender Patients. , 2022, European urology.
[8] N. Kyprianou,et al. Prostate cancer in transgender women: considerations for screening, diagnosis and management , 2022, British Journal of Cancer.
[9] E. Hyams,et al. The state of PSA counseling in male‐to‐female transgender patients in the U.S. , 2022, The Prostate.
[10] P. Verze,et al. Hyperbaric oxygen therapy as adjuvant treatment for surgical site infections after male‐to‐female gender affirmation surgery: A 10‐year experience , 2022, Andrology.
[11] J. Meningaud,et al. Prostate cancer awareness among transgender women after gender‐affirming surgery , 2022, The Prostate.
[12] M. Emberton,et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature. , 2021, European urology focus.
[13] H. Ahmed,et al. Prostate cancer in transgender women: what does a urologist need to know? , 2021, BJU international.
[14] I. Ouzaid,et al. Is it Worth Starting Sexual Rehabilitation Before Radical Prostatectomy? Results From a Systematic Review of the Literature , 2021, Frontiers in Surgery.
[15] A. Jemal,et al. Cancer Stage, Treatment, and Survival Among Transgender Patients in the United States , 2021, Journal of the National Cancer Institute.
[16] M. Irwig,et al. Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review , 2021, Journal of General Internal Medicine.
[17] Anurag K. Singh,et al. Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals. , 2020, European urology.
[18] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[19] M. den Heijer,et al. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment , 2020, The Journal of clinical endocrinology and metabolism.
[20] Mandi L. Pratt-Chapman,et al. Provider Recommendations Are Associated with Cancer Screening of Transgender and Gender-Nonconforming People: A Cross-Sectional Urban Survey , 2020, Transgender health.
[21] J. Motmans,et al. Epidemiological considerations in transgender health: A systematic review with focus on higher quality data. , 2020, International journal of transgender health.
[22] Richard J Lee,et al. Prostate cancer in transgender women. , 2018, Urologic oncology.
[23] A. Jemal,et al. Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data. , 2018, Cancer epidemiology.
[24] Ariella R. Tabaac,et al. Gender Identity Disparities in Cancer Screening Behaviors. , 2018, American journal of preventive medicine.
[25] O. Franco,et al. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study , 2017, Systematic Reviews.
[26] R. Autorino,et al. Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges. , 2017, Urology.
[27] T. Lash,et al. Cohort study of cancer risk among insured transgender people. , 2017, Annals of epidemiology.
[28] G. Prins,et al. The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? , 2017, The Prostate.
[29] S. Elzanaty,et al. Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population , 2017, Current Urology.
[30] M. Matrana,et al. Metastatic Prostate Cancer 35 Years After Sex Reassignment Surgery. , 2016, Clinical genitourinary cancer.
[31] L. Gooren,et al. Prostate cancer incidence in orchidectomised male‐to‐female transsexual persons treated with oestrogens , 2014, Andrologia.
[32] C. Chew‐Graham,et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews , 2014, BMC Health Services Research.
[33] S. Prescott,et al. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[34] I. Kaplan,et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. , 2006, JAMA.
[35] D. Newling,et al. Metastatic prostatic carcinoma in a male-to-female transsexual. , 1998, British journal of urology.